Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets - Schedule of Intangible Assets (Details)

v3.23.1
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Apr. 01, 2023
Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]    
Intangible assets from discontinued operations $ 0 $ 735
Intangible assets, gross 22,860 23,595
Less accumulated amortization (3,926) (3,563)
Total intangible assets 18,934 20,032
Patents and Domains    
Finite Lived Intangible Assets [Line Items]    
Intangible assets, gross 4 4
Computer Software    
Finite Lived Intangible Assets [Line Items]    
Intangible assets, gross 3,563 3,563
Soin Intangibles [Member]    
Finite Lived Intangible Assets [Line Items]    
Intangible assets, gross [1] $ 19,293 $ 19,293
[1] The Soin intangibles acquired by the Company consist of the following:
1.
Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;
2.
Final formula for Naltrexone; and
3.
Orphan drug designation as approved by the FDA.